Table 15.10
Immunosuppression Use for Maintenance by Regimen
Two Years Following Transplantation, 1998 to 2003
Recipients with Kidney-Pancreas Transplants

	Transplant Year					
	1998	1999	2000	2001	2002	2003
Transplants	972	942	915	891	905	871
Functioning Graft at 2 Years PostTx	828	818	797	750	776	739
With Maintenance Use Recorded at 2 Years PostTx	797	787	781	723	765	727
--- + MMF/MPA	0.0%	0.0%	0.0%	0.1%	0.0%	0.3%
--- + MMF/MPA + Siro/Evero	0.0%	0.0%	0.0%	0.6%	0.3%	1.8%
--- + MMF/MPA + Steroids	0.4%	0.5%	0.3%	0.8%	0.9%	0.0%
--- + OtherAntimet + Steroids	0.1%	0.0%	0.0%	0.0%	0.0%	0.0%
--- + Siro/Evero	0.0%	0.0%	0.0%	0.1%	0.4%	0.1%
--- + Siro/Evero + Steroids	0.0%	0.6%	0.5%	0.3%	0.4%	0.7%
--- + Steroids	0.4%	0.3%	0.0%	0.8%	0.8%	0.6%
CyA	0.1%	0.0%	0.0%	0.1%	0.4%	0.0%
CyA + MMF/MPA	0.0%	0.0%	0.0%	0.3%	0.3%	0.4%
CyA + MMF/MPA + Siro/Evero	0.0%	0.1%	0.3%	0.0%	0.0%	0.0%
CyA + MMF/MPA + Steroids	23.6%	19.4%	11.0%	9.3%	8.4%	7.4%
CyA + OtherAntimet	0.0%	0.0%	0.1%	0.0%	0.0%	0.0%
CyA + OtherAntimet + Steroids	1.4%	0.1%	0.1%	0.1%	0.4%	0.0%
CyA + Siro/Evero	0.0%	0.1%	0.1%	0.3%	0.3%	1.2%
CyA + Siro/Evero + Steroids	0.4%	0.9%	2.6%	2.6%	1.0%	1.5%
CyA + Steroids	1.3%	1.0%	1.3%	1.1%	0.1%	0.4%
Tac	0.6%	0.1%	0.3%	1.8%	2.7%	1.4%
Tac + MMF/MPA	1.4%	2.4%	3.7%	5.3%	5.9%	7.6%
Tac + MMF/MPA + OtherAntimet	0.0%	0.0%	0.1%	0.0%	0.0%	0.0%
Tac + MMF/MPA + Siro/Evero	0.0%	0.0%	0.3%	1.0%	0.4%	1.0%
Tac + MMF/MPA + Steroids	53.1%	55.9%	53.3%	46.7%	48.9%	50.6%
Tac + OtherAntimet	0.3%	0.5%	0.1%	0.0%	0.3%	0.1%
Tac + OtherAntimet + Steroids	4.0%	3.3%	2.8%	0.8%	2.5%	1.9%
Tac + Siro/Evero	0.0%	0.4%	3.3%	7.7%	8.1%	9.4%
Tac + Siro/Evero + Steroids	1.4%	2.0%	6.4%	11.1%	8.6%	5.1%
Tac + Steroids	7.4%	7.5%	5.9%	5.1%	5.0%	5.0%
Other Regimen	4.3%	4.7%	7.6%	3.9%	4.1%	3.6%

Source: OPTN/SRTR Data as of May 1, 2006.
Notes:

Percentages are calculated based on the total number of patients with maintenance use at two years following transplantation. They sum to 100 percent for each column.
Transplants prior to year 1998 are not reported due to insufficient reporting of immunosuppressive drug use.
---: No Calcineurin Inhibitor Use; CyA: Cyclosporine; Tac: Tacrolimus.
MMF: Mycophenolate Mofetil; MPA: Mycophenolate Sodium; Siro: Sirolimus; Evero: Everolimus; OtherAntimet: Antimetabolites excluding MMF and MPA.
"Other Regimen" includes drug combinations that are different from the listed regimens and drugs from the text field entering.